Balixafortide联合艾日布林治疗HER2阴性转移性乳腺癌的1期剂量递增试验
这项单臂1期试验在56例经治HER2阴性转移性乳腺癌患者中评估CXCR4拮抗剂balixafortide联合艾日布林的安全性和初步活性。54例可评估患者中16例(30%;95% CI 18-44)出现客观缓解(均为部分缓解)。
要点
- 未确认剂量限制性毒性,未达到最大耐受剂量。
- 客观缓解率30%(95% CI 18-44),均为部分缓解。
- 常见不良事件为疲乏、中性粒细胞减少和输液相关反应。
核心结论
- balixafortide联合艾日布林的安全性和耐受性似乎与艾日布林或balixafortide单药相似。
- 该联合方案在HER2阴性转移性乳腺癌患者中显示出初步活性,值得在随机试验中进一步研究。
研究设计与样本
- 单臂、剂量递增1期试验,在西班牙和美国11个中心入组56例患者。
- 采用标准3+3剂量递增设计,随后在确定的最大耐受剂量或最高剂量下扩展队列。
- 方案修订后分为两部分:部分1为28天导入周期,部分2为21天周期。
主要发现
- 56例患者中未确认剂量限制性毒性,未达到最大耐受剂量。
- 54例可评估患者中16例(30%;95% CI 18-44)出现客观缓解,均为部分缓解。
- 最常见任何级别治疗中出现的不良事件为疲乏(44/56,79%)、中性粒细胞减少(32/56,57%)、输液相关反应(27/56,48%)。
- 21/56(38%)患者发生严重不良事件,包括发热性中性粒细胞减少5例(9%)。
关键数值与推荐
- 入组条件:≥18岁女性,组织学确诊HER2阴性转移性乳腺癌,肿瘤细胞CXCR4表达,ECOG PS 0或1,既往接受1-3线转移性乳腺癌化疗,激素受体阳性者至少接受过一种内分泌治疗(除非不适合)。
临床怎么用
- 该联合方案在经重度治疗的HER2阴性转移性乳腺癌患者中显示出初步疗效和可管理的安全性。
- 结果支持在随机试验中进一步评估balixafortide联合艾日布林。
局限性
- 单臂设计,样本量小,无对照组。
- 部分1因治疗相关死亡事件而修订方案。
- 2例(4%)患者在治疗期间死亡(感染性休克和肺炎各1例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The C-X-C chemokine receptor type 4 (CXCR4)-stromal cell-derived factor-1α (SDF-1α) axis regulates function and trafficking of immune cells and the tumour microenvironment. CXCR4 antagonists have been shown to enhance the activity of different anticancer treatments in preclinical models. We assessed the safety, tolerability, pharmacokinetics, and preliminary phase 1 activity of the CXCR4 antagonist, balixafortide, in combination with eribulin chemotherapy in patients with heavily pretreated, relapsed metastatic breast cancer. METHODS: This single-arm, dose-escalation, phase 1 trial enrolled patients at 11 sites in Spain and the USA. Eligible patients were women aged 18 years or older who had histologically confirmed HER2-negative metastatic breast cancer, evidence of tumour cell CXCR4 expression, an Eastern Cooperative Oncology Group performance status of 0 or 1, and who had previously received between one and three chemotherapy regimens for metastatic breast cancer, and at least one endocrine therapy if they had hormone receptor-positive disease, unless they were considered unsuitable for endocrine therapy. A standard 3+3 dose-escalation design was used, followed by an expanded cohort at the established maximum tolerated dose or highest dose if no dose-limiting toxicity was observed for the combination. After a treatment-related fatal adverse event in the first cohort who received 21-day cycles of treatment with eribulin and balixafortide, a protocol amendment modified the study design to be done in two parts. Patients enrolled to part 1 received an initial 28-day run-in cycle, with some cohorts receiving de-escalated doses of eribulin plus balixafortide to assess the safety and pharmacokinetics of the combination. The evaluation of part 1 did not confirm any dose-limiting toxicities or eribulin-balixafortide interactions, and therefore part 2 started enrolling patients to receive eribulin at the originally planned dose of 1·4 mg/m2 on days 2 and 9 of a 21-day cycle and balixafortide from a starting dose of 2 mg/kg with dose increments of 0·5 or 1 mg/kg on days 1-3 and 8-10 of the 21-day cycle. Both drugs were administered as intravenous infusions. All patients were to receive treatment until disease progression or unacceptable toxicity. The primary endpoints were dose-limiting toxicities and adverse events, and the establishment of a maximum tolerated dose or recommended phase 2 dose, and pharmacokinetic parameters. Safety analysis was done in all patients who received at least one dose of study treatment. Analysis of antitumour activity was done in all patients who received at least one full cycle of study treatment. The trial is registered at ClinicalTrials.gov, number NCT01837095, and is closed to accrual. FINDINGS: Between Jan 28, 2014, and Oct 4, 2016, 56 patients were enrolled into the trial. No dose-limiting toxicities were confirmed and the maximum tolerated dose was not reached. The highest dose was established as eribulin 1·4 mg/m2 on days 2 and 9, and balixafortide 5·5 mg/kg on days 1-3 and 8-10 of the 21-day cycle. Objective responses (all partial responses) were observed in 16 (30%; 95% CI 18-44) of 54 patients who were evaluable for antitumour activity. The most common treatment-emergent adverse events of any grade were fatigue (44 [79%] of 56 patients), neutropenia (32 [57%]), infusion-related reactions (27 [48%]), alopecia (26 [46%]), constipation (26 [46%]), and nausea (25 [45%]). Serious adverse events occurred in 21 (38%) of 56 patients, including febrile neutropenia in five (9%) of 56 patients, neutrophil count decrease in two (4%) patients, constipation in two (4%) patients, pneumonia in two (4%) patients, and urinary tract infection in three (5%) patients. Two (4%) of 56 patients died while receiving study treatment; one from septic shock and one from pneumonia. INTERPRETATION: The safety and tolerability of balixafortide plus eribulin seems to be similar to that of eribulin or balixafortide monotherapy, and the preliminary activity of the combination seems promising in patients with HER-negative metastatic breast cancer. The results suggest that balixafortide plus eribulin has potential to provide a new therapeutic option in heavily pretreated patients with metastatic breast cancer and warrants further investigation in randomised trials. FUNDING: Polyphor.
引用
- Pernas S, Martin M, Kaufman PA, et al. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. Lancet Oncol. 2018. PMID: 29706375. doi:10.1016/S1470-2045(18)30147-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。